Stellest 2.0 Shows Early Promise

The company said in six months, Essilor Stellest 2.0 lenses achieved interim results comparable to those previously reported after 12 months with first-generation Essilor Stellest lenses.^†,1,2

The result indicates a potential accelerated treatment response, the company said.

“We are excited by these six-month interim findings for Essilor Stellest 2.0 lenses, which represent an important milestone in our long-term commitment to advancing myopia management through continuous innovation and clinical research,” said Davide Schinetti, Chief Operating and R&D Officer at EssilorLuxottica.³

“The magnitude and speed of the treatment response observed at six months are very encouraging and have not been previously observed across our Stellest clinical research ever.”

The six-month interim results were presented during an EssilorLuxottica satellite symposium at the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) Subspecialty Day, held during the European Society of Cataract and Refractive Surgeons (ESCRS) Congress in London.

Key interim findings³ included:

• Significant slowing of myopia progression and axial elongation on average, compared with single-vision spectacle lenses, with treatment effects of 0.51 D and 0.21 mm respectively.
• High wearing compliance, with more than 90% of children in both groups wearing their spectacles for more than 12 hours per day, seven days per week.
• Adaptation and wearer comfort were as good as with single-vision lenses, with 98% of children fully adapting within one week.

Essilor Stellest spectacle lenses use highly aspherical lenslet target (HALT) technology.* The interim results are based on an ongoing two-year, randomised, double-masked clinical trial, being conducted in China.¹

Principal investigator, Professor Yang Xiao, from Sun Yat-sen University in China, said he was “greatly encouraged by the six-month interim results”.³

“Notably, with myopia progression remaining close to 0 D on average after six months, spectacle lenses with HALT Max technology achieved in just half a year the same level of myopia control – on both refraction and axial length – that was previously reported with HALT technology at one year,” he said.

“That means the treatment response appears to be effectively twice as fast. High wearing compliance, rapid adaptation, and consistent efficacy across younger and older children reinforce the practical value of this innovation in myopia control.”

† Based on interim results from an ongoing two-year, randomised, double-masked clinical trial in China (n=62 Essilor Stellest 2.0; n=58 single vision).

Indirect comparison across separate randomised clinical studies. Treatment effects versus single vision lenses were SER: 0.51 D and AL: 0.21 mm on average at six months in the ongoing Essilor Stellest 2.0 lens two-year, randomised, double-masked, two-arm clinical trial conducted in Guangzhou, China, compared with SER: 0.53 D and AL: 0.23 mm on average at 12 months in the Essilor Stellest lens two-year prospective, controlled, randomised, double-masked clinical trial conducted in Wenzhou, China. The studies differed in population, participant age groups, location, design, and follow-up duration (six vs 12 months), and no formal between-study statistical comparison was performed.

*HALT is an acronym for highly aspherical lenslet target and does not imply a “halt” or “stop” of myopia progression.

References

1. Essilor International. Data on File, 2026.
2. Bao J, Yang A, Chen H, et al. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-6. doi: 10.1136/bjophthalmol-2020-318367.
3. EssilorLuxottica , EssilorLuxottica unveils the best six-month treatment effects ever reported across its clinical studies on Essilor Stellest lenses (media release, 22 Sept 2026) available at: http://ml-eu.globenewswire.com/Resource/Download/4fbe9ee2-6658-4ff0-8e02-ba3d42b89f4b [accessed Sept 2026].